Nature Reviews Clinical Oncology

Papers
(The H4-Index of Nature Reviews Clinical Oncology is 83. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Tasadenoturev active in DIPG1190
A new standard of care for advanced-stage urothelial carcinoma857
From little subclones grow mighty oaks811
BCMA-directed therapy for early relapsed and/or refractory multiple myeloma802
Sublobar resection is non-inferior to lobectomy in very early stage NSCLC764
First-line triplet therapy for advanced-stage PIK3CA-mutant HR+ breast cancer improves outcomes728
An early switch in first-line therapy improves outcomes of advanced-stage G/GEJC692
Novel ICI–TKI combination improves HCC outcomes680
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety596
Cancer-related accelerated ageing and biobehavioural modifiers: a framework for research and clinical care589
Hodgkin lymphoma: great progress with room for improvement585
Ecological management of the microbiota in patients with cancer582
Quantitative PET-based biomarkers in lymphoma: getting ready for primetime561
The emerging roles of circRNAs in cancer and oncology496
Current understanding and management of CAR T cell-associated toxicities496
Gut microbiota in colorectal cancer development and therapy495
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials432
From ESMO 2022429
From the ESMO Congress 2021417
Mortality is similar with active monitoring402
Contrasting results with second-line CAR T cells in large B cell lymphoma353
Ponatinib superior to imatinib in Ph+ ALL348
Adjuvant immunotherapy for NSCLC — does treating earlier mean treating better?344
Sacituzumab tirumotecan improves OS in mTNBC343
Daratumumab and missed sequencing opportunities in transplant-ineligible multiple myeloma: lessons for future trials339
Personalized neoantigen mRNA vaccine mitigates melanoma recurrence316
Minimal residual disease as a target for liquid biopsy in patients with solid tumours307
Understanding and overcoming multidrug resistance in cancer293
Humanized mouse models for immuno-oncology research259
Early MRD predicts disease recurrence and benefit from adjuvant chemotherapy in CRC255
Predicting cancer outcomes with radiomics and artificial intelligence in radiology254
Harnessing cytokines and chemokines for cancer therapy243
Ipilimumab plus nivolumab efficacious in patients with dMMR/MSI-H disease237
Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours228
Craniospinal irradiation improves leptomeningeal metastasis control225
Survival benefit with second-line combination in endometrial cancer223
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma222
Adding immune-checkpoint inhibitors to chemotherapy extends survival in endometrial cancer222
Spatial landscapes of cancers: insights and opportunities218
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs218
Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response216
Adding lurbinectedin to maintenance therapy improves outcomes in ES-SCLC211
Promises and pitfalls of multi-cancer early detection using liquid biopsy tests207
Harnessing big data to characterize immune-related adverse events196
Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship189
Improving outcomes in patients with oesophageal cancer183
Biomarkers for immunotherapy of hepatocellular carcinoma181
Approvals in 2022: overall survival, dose optimization, new approvals and beyond179
New CAPSTONE of SCLC therapy?174
Amivantamab is effective in NSCLC harbouring EGFR exon 20 insertions170
SHINE a light: frontline ibrutinib for MCL170
Perioperative chemotherapy superior to preoperative chemoradiotherapy for locally advanced EAC163
Women with clinically node negative breast cancer can safely avoid axillary surgery162
Daratumumab in newly diagnosed MM — incorporating lessons learnt from CASSIOPEIA, MAIA and beyond156
Aumolertinib is effective in NSCLC156
First-line pembrolizumab plus lenvatinib is effective in non-clear-cell RCC154
From ESMO 2023: advances in lung cancer153
DREAMseq of therapy for BRAF-mutant melanoma144
Prospective comparisons support the use of navigational bronchoscopy142
Targeting chromosomal instability in patients with cancer142
Circulating tumour DNA — looking beyond the blood134
Long-term outcomes following CAR T cell therapy: what we know so far133
Mitigating acute chemotherapy-associated adverse events in patients with cancer128
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer125
Response to neoadjuvant endocrine therapy complements recurrence score114
Benefit with ramucirumab in mesothelioma114
Multiomics STEP up in correlative analysis of response to CAR T cells113
Author Correction: The high costs of anticancer therapies in the USA: challenges, opportunities and progress110
From the ESMO Congress 2023104
Cadonilimab is efficacious in HER2-negative advanced-stage G/GEJ adenocarcinomas101
Isatuximab–VRd quadruplet shows promise in transplant-ineligible NDMM101
Zanubrutinib succeeds in head-to-head with ibrutinib in R/R CLL100
FIRSTMAPPP prospectively charts the efficacy of sunitinib for phaeochromocytoma and paraganglioma93
HAIC-FO improves outcomes in HCC91
Enhancing immunotherapy with tumour-responsive nanomaterials90
Patritumab deruxtecan shows activity in EGFR-mutant NSCLC90
Newly approved cancer drugs in China — innovation and clinical benefit89
Clinical implications of T cell exhaustion for cancer immunotherapy89
Lung cancer in patients who have never smoked — an emerging disease89
Claudin 18.2 as a novel therapeutic target87
Targeted biopsy reduces detection of clinically insignificant cancer86
Combining CAR T cells effective in RRMM84
Author Correction: Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer83
0.064511060714722